IDEXX Laboratories

IDEXX Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings increase.

IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) stock is trading higher on Monday after it reported better-than-expected third-quarter financial results and raised its 2025 forecast.

IDEXX Laboratories' stock has significantly outperformed the broader market over the past year, but analysts are cautiously bullish about its growth potential.

Going under the radar, shares of this vet tech company have been winners this year.

In a volatile market landscape marked by rapid shifts in investor sentiment, financial experts are spotlighting key stocks and sectors poised for growth. On CNBC's “Halftime Report Final Trades,” Bryn Talkington, Managing Partner of Requisite Capital Management, recommended sticking with Tesla, Inc. (NASDAQ:TSLA).

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Monday.

Pet healthcare is witnessing a surge in demand as more households prioritize their pets’ well-being, driving companies in this sector to outperform expectations. This trend is reflected in IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) recent financial results, showcasing significant growth and revised earnings guidance.

IDEXX Laboratories has outpaced the Dow Jones Industrial Average this year, and analysts are reasonably upbeat about its future growth potential.

IDEXX Laboratories has significantly outperformed the broader market in recent months, and analysts remain cautiously optimistic about the stock’s prospects.

Despite IDEXX Laboratories’ underperformance relative to the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.